Global Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media engagement at the top of their priority lists, the study – published by specialist digital insights consultancy, Creation Healthcare –…

USA With office occupation rates on the slide and the life sciences industry’s demand for lab space on the rise, the repurposing of existing offices into medical laboratories has become an important new asset class, writes Liz Chen, a lab planner at HGA Life Science + Advanced Technology Group’s San Diego…

Global Smart manufacturing has become a key component of today’s industrial evolution and unlocked unprecedented efficiencies and quality enhancements. Smart Manufacturing expert Eric Whitley outlines the specific benefits of smart manufacturing for the pharmaceutical industry, illustrating these benefits with industry case studies.   Smart manufacturing has entered the world of modern…

Global Eli Lilly recently revealed more than promising clinical trial results for its Alzheimer’s candidate, donanemab, showing that the drug slows Alzheimer’s by as much as 60 percent in mild cases. While safety concerns about the drug remain, Lilly is hoping for an FDA approval by the end of the year.…

USA Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led to a number of breakthrough therapies. Chairman and CEO Bob Bradway recently spoke to the Money Maze podcast about the…

USA David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions. Crean expects to see a continuation of 2023’s strong start to M&A and questions whether the FTC’s newly-aggressive approach will…

USA Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken its indignation a step further and sued the US government, arguing that the new legislation violates the constitution, but shareholders at the ICCR are not…

USA Although clinical trial diversity remains high on the agendas of industry sponsors, there is still a long road to travel towards more equitable and representative research – and ultimately safer and more effective medicines. On this theme, writing in the June 2023 edition of the DIA Global Forum magazine, Jorge…

USA Speaking at the 2023 BIO International Convention Chris Viehbacher who joined Biogen as CEO only a few months ago, criticised the US’s Inflation Reduction Act (IRA), legislation that will allow Medicare to negotiate prices for the drugs it spends the most on as of 2026. Viehbacher, who was brought in…

USA While the COVID-19 pandemic was a global wake-up call for many, life sciences stakeholders argue that not enough is being done to address the rising threats of further health crises and equate health security with national security, a necessity that requires consistent public funding. In addition, as a recent panel…

USA During a panel discussion at the BIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research (CBER) discussed the positive regulatory outcomes of the COVID-19 pandemic as well as the backlogs it created and the challenges of carrying the lessons learned forward.   At…

USA During the ongoing BIO International Convention in Boston between June 5th and 8th, the US lobbying group has announced a new board chair in Ted Love as well as a new executive committee.   Love is a longstanding BIO board director and the former President & CEO of Global Blood…